Drugs / Pegcyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03381417 | Oct 2016 → Nov 2017 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegcyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03381417 ↗ |